PRINCETON, NJ and NEW YORK, NY--(Marketwire - November 10, 2008) - Ophthotech Corp. announced today the treatment of its first patient with Volociximab, a monoclonal antibody targeting alpha5beta1 integrin, in a Phase I trial for the treatment of wet age-related macular degeneration (AMD). Ophthotech is a privately held biopharmaceutical company focused on developing ophthalmic therapies for both wet and dry AMD. Volociximab represents Ophthotech's third compound in clinical development. This Phase I trial will assess the safety, tolerability and pharmacokinetic profile of Volociximab.
